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OVERVIEW — This paper summarizes liability and compensation concerns
surrounding the smallpox vaccination program announced by President Bush
on December 13, 2002. The paper examines the nature of adverse health events
that are likely to occur in connection with the smallpox vaccine, assesses the
liability protections that have been established for organizations and individu-
als participating in the vaccination program, and discusses the compensation
mechanisms being considered to address the damages incurred by volunteers
who may suffer from adverse vaccine reactions. Specifically, the implications
of the Federal Tort Claims Act, workers’ compensation programs, and the cre-
ation of a new no-fault compensation fund are explored.
2
NHPF Issue Brief No.788 / March 12, 2003
National Health Policy Forum
2131 K Street NW, Suite 500
Washington DC 20037
202/872-1390









NHPF is a nonpartisan education and
information exchange for federal
health policymakers.
Who Will Pay for the Adverse
Events Resulting from Smallpox
Vaccination? Liability and
Compensation Issues
Among the many significant changes that have evolved since the Septem-
ber 11 and anthrax attacks is the recognition that the United States is
vulnerable to once-inconceivable threats, such as bioterrorism. These
threats have created a new attitude about preparedness and have fo-
cused the attention of not only the public health community but also those
involved with homeland security. Smallpox has become a focal point of
this attention due to the enormous potential consequences of this disease
and the nation’s perceived vulnerability to this particular threat.
Concerns over a deliberate release of the smallpox virus were height-
ened immediately after the September 2001 attacks. One of the first acts
of the federal government was to insure the availability of enough small-
pox vaccine, should the worst case scenario unfold and the United States
fall victim to a smallpox attack. Over time, the plans surrounding small-
pox vaccine have been refined. Administration officials have delineated
both a “pre-event” plan to vaccinate first responders who would be
called on to address a smallpox outbreak and a “post-event” plan for
mass vaccinations of the public in the actual event of a smallpox attack.
The president’s pre-event plan calls for a three-phase approach. Phase one,
already under way, calls for the voluntary inoculation of approximately
500,000 health care workers who would be called upon to vaccinate the
public during a national emergency. Phase two calls for the inoculation of
up to 10 million additional health care workers and first responders (po-
lice, firefighters, and paramedics). Phase three would establish a process
that would allow members of the general public (adults without medical
contraindications) to receive the vaccine if they insist, although the gov-
ernment does not recommend general vaccination at this time.
The policy and legislative challenges involved with this effort are par-
ticularly difficult. The majority of the public is uncomfortable thinking
about the potential of smallpox release, and some in the health field
are distressed with the political overtones that have entered in to the
clinical debate. Still others in the public health field are concerned that
the singular focus on smallpox has compromised their ability to pro-
vide essential daily services, such as childhood vaccines and screen-
ings for sexually transmitted diseases, while at the same time detract-
ing from broader preparedness-building efforts.
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Overlaying all of these concerns is the notion of perceived risk—how
great is the smallpox risk to Americans? On balance, how much risk
versus benefit does the vaccine provide? Are today’s health providers
sufficiently well informed to adequately assess and balance the risks of
a smallpox attack against the risks inherent in the smallpox vaccination?
What are the legal and ethical ramifications of pre-event vaccination?
While the risk-benefit calculation for all vaccines represents a departure
from ordinary medical care in that healthy people are injected with some-
thing that may make them sick, the risk profile of the smallpox vaccine is
particularly problematic. The smallpox vaccine has a higher percentage
of known (and potentially dangerous, even life-threatening) side effects;
it has not been given routinely in the United States for the past 30 years; it
is administered differently than other vaccines; and, perhaps most con-
founding, the risks of contracting smallpox are almost impossible to quan-
tify. Adding to the concerns of health providers is the fact that the
president’s smallpox vaccine plan is unfolding in today’s litigious health
care environment, one that is teetering on the brink of a liability and mal-
practice crisis.
In light of the various concerns and challenges, a number of the almost
3,600 hospitals deemed eligible by the Centers for Disease Control and
Prevention (CDC) to form smallpox response teams have already declined
to participate. By some accounts,1  close to 350 hospitals across the coun-
try are forgoing the vaccinations. Although this reluctance to participate
in the smallpox vaccination program stems from a variety of rationales,
financial concerns regarding liability exposure and compensation for those
who suffer from adverse vaccine reactions have been identified as impor-
tant impediments to broader participation in the vaccination program.
RISKS ASSOCIATED WITH THE SMALLPOX VACCINE
The smallpox vaccine, called Dryvax, does not contain inactivated or at-
tenuated smallpox virus. Rather it uses an organism called vaccinia (a live
cowpox virus), which is grown from calf lymph,2  resembles smallpox in
many ways, and triggers an immune response that offers protection
against smallpox. Because it is a live virus, vaccinia can cause severe reac-
tions in those vaccinated, particularly for immune-compromised individu-
als, and can be transmitted from vaccinated persons to others until the
injection site scabs over.
Smallpox vaccination poses a number of rare but significant health risks,
both for persons who are vaccinated and for those who are exposed to
vaccinia through secondary transmission. Non-life-threatening side effects
of the smallpox vaccine can include local inflammation, rashes, fever,
headaches, muscle pain, fatigue and weakness, and nausea. Life-threat-
ening reactions can include encephalitis. Experts have estimated that, out
of one million people vaccinated, approximately 1,000 will experience
serious, though not life-threatening, reactions; between 14 and 52 out of
Smallpox vaccination
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one million vaccinated for the first time will experience potentially life-
threatening reactions; and one to two people will die.3  Instances of sec-
ondary transmission, or inadvertent inoculation, may occur in 20 to 60
cases for every one million persons vaccinated. At high risk of adverse
reactions are pregnant women, young children, immunocompromised
patients (that is, those who are undergoing chemotherapy, are HIV-posi-
tive, or have received transplants), patients with autoimmune diseases
such as lupus or rheumatoid arthritis, as well as those who have or have
had eczema or other skin conditions.4
Information on the risks of smallpox vaccine is based on historical data
gathered when smallpox was an immediate disease threat and vaccina-
tions were routine. The United States stopped routine smallpox vaccina-
tion of Americans in 1972.5  The last natural case of smallpox was recorded
in Somalia in 1977, and in 1980 the disease was declared officially eradi-
cated by the World Health Organization. It has been a long time since the
smallpox vaccine has been administered to large numbers of people. In
fact, the smallpox vaccine currently available was manufactured in 1975,
freeze-dried, and stored in vials.
While the nature of the U.S. population and the proportion of vulnerable
persons has changed dramatically since the 1970s, experts believe that by
carefully (and confidentially) screening out high-risk volunteer vaccinees,
including those who are unaware they may be ill, the number of vaccinees
experiencing serious side effects could be dramatically reduced. Simi-
larly, experts have stressed that educating both the vaccinator and the
vaccinee in the proper care of the injection site (keeping the site covered
until it scabs over to avoid accidental exposure) will result in a decreased
incidence level of secondary transmission.
Although a number of steps could be taken to minimize the risks associ-
ated with the vaccine, including volunteer education, thorough screen-
ing,6  and careful implementation, adverse reactions to the vaccine will
occur. The establishment of financial protections related to these antici-
pated adverse events has yet to be completely resolved, leaving many
health care workers uneasy. These financial concerns can be divided into
the need for broader liability protection and the assurance that compen-
sation for lost workdays and uncovered health costs will be guaranteed,
given the potential health risks associated with the smallpox vaccine.
LIABILITY PROTECTION
Over the years, vaccine policy has become ensnared in a tangled legal
web. While many herald vaccines as public health miracles that contrib-
ute to the public good, others question their safety and wonder about
potential links to disease. Vaccine injury and the right to sue for vaccine-
related injuries have been hotly debated issues recently, particularly in
regard to some childhood vaccines.
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With these liability concerns as a backdrop, the drafters of the Home-
land Security Act of 2002 sought to address (through Section 304 of the
act) the issue of liability protection as it pertains to the smallpox vaccine.
While on the one hand, some consumer advocates are concerned that
Section 304 has limited patients’ rights to sue, on the other, health care
providers, both individuals and organizations, are concerned whether
the scope of protection for health care workers is sufficiently broad.
Section 304 of the Homeland Security Act deems those entities and in-
dividuals involved in the manufacture, distribution, and administration
of the smallpox vaccine as employees of the Public Health Service for tort
liability purposes. Specifically, Section 304 defines covered persons or
covered entities as the following:
■ Manufacturers and distributors of a smallpox vaccine (referred to as
a countermeasure).
■ Health care entities (for example, hospitals and clinics) under whose
auspices a smallpox vaccine is administered.
■ Licensed health professionals or other individuals who are autho-
rized to administer the vaccine under state law.
By deeming these covered persons or entities as employees of the federal
government, the Homeland Security Act effectively transfers liability from
these private-sector parties to the federal government under the auspices
of the Federal Tort Claims Act (FTCA). Individuals seeking redress for
harm caused by the smallpox vaccine are limited to the remedies avail-
able under the FTCA.
To place the smallpox liability issue in greater context, it is helpful to be
familiar with the conceptual underpinnings of the FTCA.7  Historically,
the notion that the U.S. government should be immune from suit was
rooted in American law and is believed to have derived from English law
and the theory that the king could do not wrong. “Sovereign immunity,”
as the theory is known, has come to rest on the rationale that the “sover-
eign is exempt from suit [on the] practical ground that there can be no
legal right against the authority that makes the law on which the right
depends.”8  As the role of the U.S. government evolved and more uncom-
pensated losses were seen, Congress enacted the Federal Tort Claims Act
in 1946.
Though limited in nature, the FTCA provides a waiver of the federal
government’s sovereign immunity. The law allows individuals to recover
from the U.S. government for property damage, personal injury, and
wrongful death caused by the negligence of a federal employee acting
within the scope of employment. Under the FTCA, the United States is
liable for the acts of its employees “in the same manner and to the same
extent as a private individual under similar circumstances.”9  In essence,
this means that if a private individual would be liable, the government is
liable. The United States cannot be sued for acts that are strictly govern-
mental and incapable of being performed by an individual.
The Homeland Security
Act effectively transfers
liability to the federal
government.
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Among many other limitations to the act, the government is not liable
for most intentional acts of its employees, including assault and battery,
and the FTCA bars courts from awarding punitive damages against the
government. The law that governs FTCA cases is the law of the states in
which the negligent acts occurred, including any limitations on dam-
ages. Defendants being sued under FTCA are represented in court by
the Department of Justice, which bears the costs of these proceedings.
The concept of negligence is important as it relates to FTCA generally
and the smallpox question specifically. For example, although individu-
als and organizations are generally shielded from liability related to the
smallpox vaccine, Section 304 provides for the federal government to seek
to recover any damages it pays to a third party injured by the smallpox
vaccine if the covered entity engaged in any acts that constitute gross neg-
ligence (“recklessness or willful disregard for the safety of others”), reck-
lessness, illegal conduct, or willful misconduct. Examples could include
negligent manufacturing of the vaccine, negligent screening, negligent
injection, and a failure to warn those being injected about the possible
adverse effects of the vaccine. But, it is not yet clear what standard will be
applied in determining whether someone has engaged in “grossly negli-
gent, reckless, or illegal conduct or willful misconduct.”
Potential Liability Gaps under Section 304
While Section 304 provided important liability protections, gaps still re-
main. There appear to be classes of sponsoring organizations that may
not qualify for liability protection under the Homeland Security Act. Critics
generally point to two important omissions: (a) hospitals or other health
care organizations that ask their employees to volunteer for the vaccine
but are not directly responsible for administering the vaccine and (b) health
care workers who are vaccinated and may inadvertently pass the vaccinia
virus to an unvaccinated person.
The American College of Emergency Physicians, for example, is con-
cerned that, even though its members will be on the front line of this
effort, they may not be covered under the current Section 304 provision.
Because many emergency physicians will be inoculated but may not
have vaccinated others (that is, they have not administered the counter-
measure), they do not fall within the liability protections stipulated under
Section 304. They are not currently considered “covered entities” or
agents of a covered entity. These providers, who could transmit the vac-
cinia virus to others who could experience serious complications, might
be held liable for these injuries.
Although the Department of Health and Human Services (DHHS) and
the Department of Justice (DOJ) have issued guidance documents which
suggest that Section 304 would be interpreted to include vaccinated health
workers, given that they would be acting within the scope of employ-
ment defined by covered entities identified in the act, many provider
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groups remain uncertain. Among the questions that health providers
are asking are the following:
■ How long after health care workers are inoculated are they pro-
tected under Section 304?
■ How is the “scope of employment” defined? In other words, if a
newly inoculated health care worker finishes a shift at the health care
facility and takes the subway home, during which time he or she
inadvertently spreads infection to another rider, is he or she protected
under Section 304?
■ Because of staff shortages, many hospitals rely on “registries” to
find temporary staff or have a variety of contractual relationships
with groups of nurses and physicians. Will contracted or temporary
employees be covered under Section 304?
These lingering unanswered questions, the moving target nature of the
program, and the lack of the full force of legislation or regulatory change
have left many on the front lines of health care jittery. These and other
similar questions are breaking new ground and are open to interpreta-
tion in the courts. This ambiguity is unsettling for many health care work-
ers who are calling for more definitive statutory language regarding
broader liability protections.
COMPENSATION QUESTIONS
While Section 304 provides liability protection to institutions involved in
the smallpox vaccine program, it does not establish a clear avenue of com-
pensation for individuals who incur injuries caused by administration of
a smallpox countermeasure (that is, the vaccine). The risks associated with
the vaccine range from relatively minor events (for example, health care
workers missing several days of work due to vaccine reactions) to severe
disability or death. In addition to the small number of serious adverse
reactions anticipated, the CDC predicts that about 30 percent of those
receiving the smallpox vaccine will be unable to work for a period of time
due to minor reactions. These risks, both minor and life-threatening, are
present even when the vaccine is administered exactly according to pro-
scribed protocols. Therefore in many (if not most) cases of adverse reac-
tion to the vaccine, provider negligence will not be a factor and redress
under the Federal Tort Claims Act will not be feasible.
Critics have argued that it is not fair to expect health care workers to
assume the risks associated with the vaccine without providing some form
of compensation to those who will suffer bad outcomes. Some observers
have attributed providers’ unwillingness to participate in the program to
the lack of adequate compensation mechanisms. Providers’ decisions
about whether or not to participate in the vaccination program are clearly
not limited to a simple financial calculation and involve a more complex
assessment of perceived risks, benefits, and responsibilities. However,
legitimate concerns regarding compensation are an important component
Section 304 does not es-
tablish a clear avenue of
compensation.
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of this decision making process, and the compensation mechanisms cur-
rently being considered are receiving close scrutiny.
Workers’ Compensation
Workers’ compensation programs are often cited as an expected source
of compensation for health care providers who suffer adverse effects
caused by the smallpox vaccine. Workers’ compensation programs, the
first form of social insurance in the United States, provide benefits to
workers who are injured on the job or who contract a work-related ill-
ness. These benefits include cash payments designed to partially replace
lost wages for time spent away from work, reimbursement for medical
care associated with the work-related illness or injury, and survivor ben-
efits (in cases of fatality) to partially restore the lost wages of a deceased
wage earner.
Workers’ compensation programs are designed and administered by the
states and vary significantly across states in terms of eligibility, benefits,
and other program design features. Although structured by state statute,
workers’ compensation programs are financed almost exclusively by
employers. Every state, except Texas, mandates participation in workers’
compensation insurance for most employers.
While the vast majority of U.S. workers have worker’s compensation ben-
efits through the state programs, not all workers are covered in this man-
ner.10  Employees of some units of state and local governments, such as
police and firefighters, are typically exempt from workers’ compensation
and receive benefits through separate programs. Civilian employees of
the federal government receive workers’ compensation benefits through
the Federal Employees Compensation Act, and U.S. military personnel
are covered by federal veterans compensation programs. A small pro-
portion of workers, such as the self-employed, certain types of agricul-
tural workers, and U.S. Merchant Marines, do not have workers’ com-
pensation benefits.
Private insurance carriers remain the primary provider of workers’ com-
pensation benefits. Exclusive state funds or self-insurance mechanisms
are also used by some states. Employers’ premiums are based on their
industry classification and the occupational classifications of their work-
ers. Most large employers are also experience-rated, which results in higher
premiums for employers whose past experience demonstrates that their
workers are at greater risk of occupational injuries or disease than other
workers in the same industry.
Questions have been raised by health care workers’ unions and others
regarding the adequacy of workers’ compensation programs for the
purposes of compensating individuals injured as a result of participa-
tion in the smallpox vaccine program. A joint workgroup of the Associa-
tion of State and Territorial Health Officials and National Association of
Health care workers’
unions and others have
raised questions  about
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City and County Health Officials examined this concern and identified
the following issues:11
■ Persons infected with vaccinia through secondary transmission from
vaccinated persons are not likely to be protected under workers’
compensation programs. Experts believe that most cases of secondary
transmission will occur in individuals who have very close personal
contact with vaccinated persons, such as family members and, poten-
tially, patients. If such individuals were to contract vaccinia from a
vaccinated person, it is highly unlikely that the victims of secondary
transmission would be exposed in a context related to their work.
Therefore, workers’ compensation would likely provide little, if any,
financial protection to victims of secondary transmission.
■ The “voluntary” nature of the smallpox vaccine may preclude
compensation under workers’ compensation programs. Each state
program has its own rules for determining if an illness can be consid-
ered work-related and thus compensable under its workers’ compensa-
tion program. Given the voluntary nature of the smallpox vaccine,
some observers have questioned if adverse events resulting from the
vaccine would be covered. If not required for employment, would the
vaccine be considered outside the scope of employment responsibilities
and thus not work-related? Because there is no contemporary experi-
ence with the smallpox vaccination program, it is difficult to conclu-
sively ascertain how each state would determine eligibility under these
circumstances.
■ Not all providers participating in the vaccine program will be
eligible for workers’ compensation protection. States generally exempt
from workers’ compensation programs certain categories of workers,
such as those employed in very small firms (for example, firms with
fewer than four employees). Neither are self-employed persons covered
by workers’ compensation programs. A significant proportion of the
workers who might be candidates for vaccination (for example, emer-
gency room physicians and nurses) may not be employees of the
hospitals in which they work but may be working as contracted labor.
If these employees are independent contractors, they will not likely be
eligible for workers’ compensation benefits.
■ Most states impose waiting periods for wage replacement payments
that make workers’ compensation programs unsuitable coverage for
very short-term, temporary disability. All states have imposed waiting
periods during which disabled workers are ineligible for cash benefits
to replace lost wages. These waiting periods range from three to seven
days. Given that the vast majority of vaccine-related adverse events are
likely to be minor, resulting in only a few days of missed work, work-
ers’ compensation programs will not compensate for the lost wages
associated with these absences. Health care providers would typically
need to use their annual or sick leave benefits, if available, to cover this
time off the job.
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■ Wage replacement levels are limited, particularly for high-wage
earners. In instances of more severe disability or death resulting from
the vaccine, compensation levels are limited, particularly for high-
wage earners. Workers’ compensation benefits only cover a fraction of
the worker’s pre-injury wage (for example, two-thirds of weekly
salary) and states have generally instituted weekly benefit limits or
caps. While it is difficult to determine “average” benefits in light of
the diversity of state programs and specific benefit rules, an illustra-
tive example helps to clarify the coverage limits.12  In the District of
Columbia, the family (a spouse and two children) of a deceased health
care worker earning $90,000 annually would be eligible for survivor
benefits of $49,296 each year under workers’ compensation, only 55
percent of the deceased workers’ annual salary. Many other states,
including both Maryland and Virginia, would offer even less generous
benefits, 39 percent and 35 percent of pre-injury salary, respectively.
Furthermore, most states do not adjust benefit amounts annually to
keep pace with inflation. While cases of severe disability or death are
projected to be extremely rare, concerns over these risks, com-
pounded by the financial insecurity that could ensue, may dampen
volunteerism.
■ Costs for adverse events are likely to be borne by employers. Em-
ployers, such as hospitals and other health care entities, are concerned
that the smallpox vaccine program will increase their workers’ compen-
sation expenses (that is, premiums). If their workers file claims due to
injuries sustained from the smallpox vaccine, these costs will be re-
flected in the employers’ experience-rated workers’ compensation
insurance premiums in the future. In addition to bearing the costs of
workers’ compensation payments, employers will also have to pay for
replacement workers to cover the duties of those who may miss work
due to adverse vaccine reactions. Although the magnitude of these
costs are difficult to quantify until more people are vaccinated, some
experts maintain that adverse events due to the vaccine are likely to be
rare and should not have a significant impact on the cost of workers’
compensation insurance or staffing expenses. While costs may not be
high on average, the costs for any one employer relative to its current
experience could be significant, particularly if that employer utilizes a
high deductible policy. Others argue that any cost burden on employers
will limit willingness to participate in this voluntary smallpox vaccina-
tion program.
■ Uncertainty exists whether federal or state workers’ compensation
programs would be invoked. Further complicating matters are ques-
tions related to which workers’ compensation program would be
responsible for payment. Section 304 of the Homeland Security Act
deems covered entities as employees of the Public Health Service, and
this “covered entities” language has been interpreted by DHHS to
include those being vaccinated. Therefore, federal, rather than state,
workers’ compensation rules and benefits could apply.
Concerns over these
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These and other emerging issues raise questions regarding the suffi-
ciency of workers’ compensation programs for providing compensation
to those injured from the smallpox vaccine, particularly if the goal is to
encourage participation in the voluntary program.
Other Potential Sources of Compensation
In addition to workers’ compensation, other potential immediate sources
of financial assistance could come from private disability insurance poli-
cies, private health care policies (some have expressed concern over the
40 million uninsured Americans who do not have health insurance), and
ultimately Social Security disability benefits, Medicare, and life insurance
policies. All of these avenues of redress would be breaking new ground
within the smallpox vaccine scenario and it is not clear how well these
compensation mechanisms would work.
The American College of Emergency Physicians (ACEP) expressed con-
cern over these various short-term financial assistance options in a Janu-
ary 8, 2003, letter to the secretary of DHHS:
ACEP believes that each of these potential sources of near-term financial
support has serious shortcomings. For example, although financial sup-
port from private disability insurance policies ultimately will depend on
how the particular policy is written, the fact that a health care profes-
sional underwent vaccination voluntarily and with notice of the poten-
tial for adverse consequences could undercut a claim for benefits under
such a policy. Similar problems arise for their health care and life insur-
ance policies. Finally, there are substantial delays in the Social Security
disability determination process, and individuals who qualify for such
benefits must wait two years before becoming eligible for Medicare.
These concerns echo some of the limitations cited with respect to work-
ers’ compensation and cast further doubt on the sufficiency of existing
mechanisms to compensate those who suffer from adverse outcomes
related to the smallpox vaccine.
Smallpox Vaccine Compensation Fund
Given the limitations of workers’ compensation and other insurance op-
tions, many stakeholders, including some state officials, public health
officers, physician groups (such as ACEP), and some of the largest health
care worker unions, have called for the creation of a no-fault, federally
financed smallpox vaccine injury compensation fund to insure adequate
financial recompense. Rep. Henry Waxman (D-Calif.) has introduced a
bill (H.R. 865) to establish such a fund, and the administration has issued
its own compensation proposal modeled after the benefits provided to
police and firefighters who die or are disabled in the line of duty. While
congressional leaders from both parties have signaled their support to
address the issue, the specific design of a smallpox compensation mecha-
nism is currently being debated.
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Proponents of a new vaccine injury compensation fund point to the cur-
rent National Vaccine Injury Compensation Program (VICP),13  which
Congress passed as part of the 1986 National Childhood Vaccine Injury
Act, as a potential model for smallpox. The VICP represents a novel ap-
proach for compensating people who suffered a vaccine-related injury.
Rather than suing the vaccine manufacturer and vaccine administrators,
those who believe they were injured (or that their child or children were
injured) file a claim under the program.
Individuals can qualify for compensation in one of three ways: (a) a peti-
tioner must demonstrate that an injury listed on the VICP Vaccine Injury
Table occurred, (b) a petitioner must prove that the vaccine significantly
aggravated a pre-existing condition, or (c) the petitioner must prove the
vaccine caused the condition. The table lists specific injuries or condi-
tions and the time frames in which they must occur following the admin-
istration of vaccine. The table identifies those conditions that are presumed
to be caused by the vaccine. Individuals with listed conditions must dem-
onstrate only that they have the injury or condition identified to receive
compensation. Individuals with conditions not listed in the table must
prove a causative relationship between their condition and the vaccine, a
much more difficult standard to meet.
The VICP, which is administered jointly by DHHS, DOJ, and the U.S.
Court of Federal Claims, pays claims from a trust fund financed by an
excise tax on vaccines.14  A DHHS physician reviews each claim to deter-
mine whether it meets the medical criteria for compensation. The DHHS
position is presented by an attorney from DOJ in hearings before a “spe-
cial master,” appointed by the federal claims court, who makes the deci-
sion for compensation under the VICP. Decisions may be appealed to the
federal claims court and to higher courts.
If a case is found eligible for compensation, the amount of award is usu-
ally negotiated between DOJ and the petitioner’s attorneys. If these par-
ties can not agree the case is heard by the special master to assess the
amount of compensation. A petitioner may file a claim in civil court against
the vaccine manufacturer or administrator only after first filing a claim
under VICP and rejecting the decision of the federal claims court.
Although there has been some discussion as to whether smallpox should
be added to the existing VICP, several arguments have been made that
do not support this approach. Some argue, for example, that it would be
difficult to add smallpox to the existing VICP because it was designed for
children who generally are not awarded damages for lost wages. Addi-
tionally, supporters of the VICP are concerned that adding smallpox to
the current fund would divert money away from the children. Another
significant difference that could make merging smallpox into the VICP
difficult lies in the financing—whereas the VICP is financed by an excise
tax on each dose of vaccine covered by the program, that mechanism
would not work for the smallpox vaccine because it is federally purchased.
13
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An alternative suggested by various health-related groups is a federally
financed smallpox vaccine injury compensation fund.
In designing a smallpox-specific vaccine injury compensation fund,
policymakers may need to consider a variety of factors, including the
following:
Eligibility — A key decision must be made regarding who will be eligible
to receive compensation. Will compensation be limited to those who vol-
unteer for vaccination, or will it be extended to include victims of sec-
ondary transmission? Will members of the general public who seek vac-
cination under “phase three” of the program, despite federal recommen-
dations against mass vaccination, be excluded? In the rare cases of fatal-
ity, who will be eligible for survivor benefits? Will employers, insurers,
or other third parties who incur costs due to vaccine injuries be permit-
ted to seek compensation from the federal fund?
Relationship to Existing Compensation Mechanisms — Another im-
portant consideration will be determining how the federal compensation
fund will function relative to other compensation mechanisms. To what
extent will claimants be allowed, required, and/or precluded from seek-
ing recompense from alternative payers, such as workers’ compensation
programs and health insurers? The federal compensation fund could be
reviewed as a “last resort” for individuals unable to receive compensa-
tion through other avenues, or it could be constructed as a sole remedy.
To what extent will claimants be allowed to pursue civil action under the
Federal Tort Claims Act, as provided for under Section 304 of the Home-
land Security Act?
Generosity of Benefits — The level of compensation that will be forth-
coming from the fund will be an important factor for providers as they
make decisions about whether or not to volunteer for the vaccine. The
existing VICP relies on negotiated settlements that are based in part on
past awards under similar circumstances. Such historical conventions do
not exist for the smallpox vaccine, making potential payment awards
ambiguous. The existing VICP establishes a $250,000 limit on pain and
suffering awards, again based on assumptions regarding the types of in-
juries commonly sustained. Injuries resulting from the smallpox vaccine
would likely differ in type and severity. Would the new fund utilize the
existing limit, set an alternative cap, leave pain and suffering award de-
terminations entirely to the federal claims court, or limit payment to “pure”
compensation for lost wages? The existing VICP also sets a $250,000 limit
on awards to victim’s estates in the event of a vaccine-related death. Given
that the existing program is designed primarily to compensate victims of
injuries incurred from childhood vaccines, such limits may not be appro-
priate for the adults likely to be injured from the smallpox vaccine.
Administrative Processes — The design of the compensation program
will have to address a broad range of administrative processes dictat-
ing how claimants can request compensation and how the fund will
How will smallpox
compensation func-
tion relative to other
mechanisms?
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operate. While many of these administrative details will be left to rule-
making, some parameters of the programs will likely be addressed in
statute. These program features are likely to include the conditions and
onset time frames to be presented in the Vaccine Injury Table that will
identify those injuries that will be presumed to be caused by the vac-
cine, as well as time limits for filing a claim. In determining which ad-
ministrative details to include in authorizing legislation, policymakers
will likely consider issues which have been raised in criticism of the
existing VICP. Although the original vaccine injury fund was established
to provide compensation “quickly, easily, with certainty and generos-
ity,”15  there has been concern over how well the VICP program has met
these goals. The U.S. General Accounting Office was asked by Sen. James
M. Jeffords (I-Vt.), then chairman of the Committee on Health, Educa-
tion, Labor and Pensions, to look at this question. The resulting Decem-
ber 1999 report, Vaccine Injury Compensation: Program Challenged to Settle
Claims Quickly and Easily, found that, while the program provided more
expedient settlement than the traditional civil tort system, the claims
process had not been as quick as expected, with only 14 percent of claims
settled in one year or less.16  Some administrative procedures may be
delineated in statute to ensure expedient processing of claims.
Efforts to ensure timely and fair compensation for all parties who incur
damages due to the smallpox vaccine must be balanced against the
government’s legitimate needs to protect against fraud and minimize fed-
eral expenditures. Policymakers will need to balance these sometimes
competing objectives while considering all of the issues discussed above.
Furthermore, some forward-thinking debate may ensue regarding the
possibility of expanding the scope of the compensation fund beyond
smallpox vaccine to include other countermeasures that may be required
for other bioterrorism threats.
As the federal government moves forward with the smallpox vaccina-
tion program, a variety of challenges are likely to emerge that will re-
quire modifications to the initial plan. Because the vaccination program
is breaking new ground, unanticipated hurdles almost certainly will be
encountered. In addition to the perceived needs for additional liability
protections and compensation mechanisms addressed above, policymakers
may consider other program changes and enhancements to shorten imple-
mentation delays and ensure program effectiveness. The Institute of
Medicine Committee on Smallpox Vaccination Program Implementation
has identified a number of issues for consideration and has issued rec-
ommendations related to the informed consent process, contraindications
screening, adverse event monitoring, guidance for the treatment of vac-
cine complications, professional training, and additional funding for the
vaccination program.17
In light of the perceived urgency of vaccinating emergency responders
against smallpox to ensure preparedness against potential terrorist at-
tacks, policymakers are under pressure to quickly adapt the vaccination
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program to address the implementation challenges that have, and will
continue to, surface. Among these many challenges, concerns related to
liability and compensation are currently producing calls for immediate
legislative action.
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